$FEMY

Elefant Dov purchased $50K of FEMY

Elefant Dov (Chief Financial Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Elefant Dov
Published Aug 12, 2026, 12:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FEMY
Neutral
low confidence
Mentioned
$FEMY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYNeutralLow
01

Why it matters

This is a primary-source insider buy, but it does not include guidance, earnings, contracts, litigation, or other fundamental updates.

02

Market read

Traders may note insider buying as a small sentiment input, but there is no new fundamental driver in the text.

03

What to watch

The article does not state whether the CFO’s purchase was funded by compensation, options exercises, or other liquidity events, limiting interpretability.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-11, covering a purchase dated 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for FEMASYS Inc (FEMY).

Company-level read

Ticker impact

$FEMYNeutralLow confidence
Context

FEMASYS CFO Elefant Dov bought 15,625 shares at $3.20 on 2026-08-07, disclosed via Form 4 filed 2026-08-11.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

Form 4 insider purchases can be informative, but this disclosure provides no new company-specific operational or financial information, and the size is relatively small.

Market effects

None indicated; this is a single-company insider transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; the filing explicitly notes no pre-arranged 10b5-1 plan, but that still does not confirm conviction or timing advantage.

Key entities

  • FEMASYS Inc

    Company whose CFO insider purchase is disclosed on Form 4.

  • Elefant Dov

    Chief Financial Officer who purchased shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.